L&C BIO Co., Ltd.'s MegaCarti Wins Best Presentation Award for Multicenter Clinical Research

[Financial News] L&C BIO Co., Ltd.'s knee cartilage treatment material, MegaCarti, has established academic evidence of its cartilage repair effects in a multicenter clinical study. Findings from a study comparing not only imaging results but also the characteristics of regenerated cartilage tissue were selected as the best presentation at an academic conference.
L&C BIO Co., Ltd. announced on the 13th that its multicenter clinical study of MegaCarti, 'LNC-MECA-004,' won the Best Presentation Award at the 2026 Fall Conference of the Korean Society of Musculoskeletal Stem Cell and Regenerative Medicine.
The study compared treatment outcomes for 61 patients aged 50 to 65 with knee cartilage damage, between a group treated with MegaCarti and a group that underwent microfracture alone. Seven medical institutions, including Sinchon Severance Hospital, Gangnam Severance Hospital and Ajou University Hospital, participated. Cartilage repair was assessed using MRI, arthroscopy and tissue examinations.
The MegaCarti group had an average MOCART score, an MRI-based measure of cartilage repair, of 52.3, higher than the control group's 42.4. Histological assessments also showed that the proportion of hyaline cartilage formation and the area of type II collagen were significantly higher in the MegaCarti group than in the control group.
L&C BIO Co., Ltd. is preparing to publish the study's findings in an academic journal. The company plans to build evidence of the product's clinical utility through additional clinical studies.

[email protected] Jung Sang-hee Reporter